Jefferies Financial Group lowered shares of Commonwealth Bank of Australia (OTCMKTS:CSLLY) from a buy rating to a hold rating in a research note published on Thursday, The Fly reports. Jefferies Financial Group also issued estimates for Commonwealth Bank of Australia’s FY2021 earnings at $2.80 EPS and FY2022 earnings at $3.26 EPS.
A number of other brokerages have also recently weighed in on CSLLY. Zacks Investment Research upgraded Commonwealth Bank of Australia from a hold rating to a buy rating and set a $108.00 price target on the stock in a research report on Monday, December 9th. JPMorgan Chase & Co. cut Commonwealth Bank of Australia from an overweight rating to a neutral rating in a research report on Wednesday, December 4th. Finally, ValuEngine cut Commonwealth Bank of Australia from a hold rating to a sell rating in a research report on Wednesday, October 2nd.
Shares of Commonwealth Bank of Australia stock opened at $105.49 on Thursday. The company has a current ratio of 2.53, a quick ratio of 1.14 and a debt-to-equity ratio of 0.81. The business’s 50 day simple moving average is $99.07 and its 200-day simple moving average is $87.05. Commonwealth Bank of Australia has a twelve month low of $65.26 and a twelve month high of $106.26.
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
See Also: Put Option
Receive News & Ratings for Commonwealth Bank of Australia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Commonwealth Bank of Australia and related companies with MarketBeat.com's FREE daily email newsletter.